Key result
Sumac supplementation improves glycemic and lipid profiles but shows no benefit on inflammatory markers.
Why the study?
Does Sumac supplementation improve cardiovascular disease risk factors in human participants?
Meta-Analysis (n=917)
Does Sumac supplementation improve cardiovascular disease risk factors in human participants?
Sumac supplementation for 4 to 12 weeks may improve glycemic and lipid profiles, suggesting potential benefits for cardiovascular risk management.
BACKGROUND: Rhus coriaria L. (Anacardiaceae), known as Sumac, is a commonly used spice, which is rich in various classes of phytochemicals including flavonoids, tannins, polyphenolic compounds, organic acids, and may be beneficial for cardiovascular disease risk factors. This comprehensive systematic review and meta-analysis aimed to assess the impact of Sumac supplementation on cardiovascular disease risk factors, including anthropometric measures, glycemic profile, inflammatory markers, and lipid profile. Additionally, we explored the dose-response relationship and optimal duration of Sumac supplementation for its effects on cardiovascular risk factors. METHODS: Relevant randomized clinical trials were identified through electronic database searches (PubMed, Scopus, Web of Science, CENTRAL, and EMBASE) up to March 2025. The Cochrane risk-of-bias tool was employed to evaluate study quality. Standardized mean differences (SMDs) in changes between intervention and placebo groups were calculated. A random-effects model, meta-regression, and non-linear modeling explored heterogeneity, dose-response relationships, and the overall impact of Sumac supplementation. RESULTS: Fifteen trials, with interventions ranging from 4 to 12 weeks and involving 917 participants, were included. Sumac supplementation demonstrated significant improvements in glycemic and lipid profile. Conversely, no significant effects were observed on other cardiovascular risk factors. CONCLUSIONS: Sumac supplementation improved lipid profile, and glycemic parameters suggesting potential benefits in addressing cardiovascular risk factors, despite no significant effects on inflammatory parameters.
No takes yet. Share an insight, caveat, or question.
Jafari et al. (2025) conducted a meta-analysis in Cardiovascular disease risk factors (n=917). Sumac supplementation vs. Placebo was evaluated on Cardiovascular disease risk factors (anthropometric measures, glycemic profile, inflammatory markers, and lipid profile). Sumac supplementation significantly improved glycemic and lipid profiles across 15 trials (N=917), though it showed no significant effects on inflammatory markers or other cardiovascular risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: